- From 1977 to 1993, U.S. guidance effectively excluded most women of childbearing potential from early-phase drug trials, so much foundational safety data was collected in men.
- The 1993 NIH Revitalization Act first required women to be included in NIH-funded clinical research, and a 2016 NIH policy extended that to considering sex as a biological variable in preclinical animal studies.
- Because peptide research skews early-stage and preclinical, a large share of it still runs in male animals and male cell lines, which is why female-specific evidence for many peptides simply does not exist yet.
Read enough peptide research and a pattern surfaces that is hard to unsee: the subjects are almost always male. Male rats, male mice, male cell lines, and, when a compound finally reaches people, study populations that still skew male. This is not a coincidence and it is not ancient history. It is the direct legacy of decades of research policy, and it is the single biggest reason a sex-disaggregated database is worth building at all.
How protection became exclusion
The modern pattern begins with two drug tragedies. In the late 1950s and early 1960s, thalidomide, prescribed for morning sickness, caused severe birth defects in thousands of infants. Around the same period, diethylstilbestrol (DES), given to prevent miscarriage, was later linked to cancers and reproductive harm in the daughters of women who took it. The lesson regulators drew was protective: keep drugs away from women who could become pregnant.
In 1977, the U.S. Food and Drug Administration issued guidance recommending that women of childbearing potential be excluded from early-phase (Phase I and early Phase II) drug studies. The intent was to shield a hypothetical fetus. The effect was that the foundational dose-finding and safety work for a generation of drugs was done overwhelmingly in men, and the results were quietly assumed to generalize.
They do not always generalize. Women are not smaller men. Body composition, hepatic enzyme activity, renal clearance, gastric emptying, and the monthly hormonal cycle all shift how a compound is absorbed, distributed, and cleared. The most cited modern example is zolpidem (Ambien): in 2013, after years on the market, the FDA cut the recommended dose for women roughly in half because women clear the drug more slowly and next-morning impairment was higher. The pharmacology had not changed, the willingness to measure it in women had.
The policy correction, and why it came late
The reversal came in stages. In 1993, the NIH Revitalization Act made the inclusion of women and minorities in NIH-funded clinical research a legal requirement, and the FDA lifted its 1977 exclusion the same year. This was genuine progress, but it applied to clinical research, the human-trial stage. It said nothing about the animal and cell studies that come first and shape which compounds ever reach people.
That gap stayed open for another two decades. Only in 2016 did the NIH begin requiring grant applicants to consider sex as a biological variable (SABV) in preclinical research, to use both male and female animals and cells, or to justify why not. Reviews of the published literature had found that many fields still defaulted to male animals, often without stating why, and frequently without analyzing results by sex even when both were used.
| Year | What changed |
|---|---|
| 1977 | FDA guidance recommends excluding women of childbearing potential from early-phase drug trials. |
| 1993 | NIH Revitalization Act requires women in NIH clinical research; FDA reverses its 1977 exclusion. |
| 2001 | A landmark Institute of Medicine report concludes sex 'matters' from cell to society. |
| 2013 | FDA halves the recommended zolpidem dose for women, a public example of a sex-difference missed for years. |
| 2016 | NIH requires sex be considered as a biological variable in preclinical (animal and cell) research. |
Why this hits peptides especially hard
Peptide research sits disproportionately at the early, preclinical end of the pipeline, exactly the stage the 1993 clinical rules never touched and the 2016 SABV policy only recently reached. Many of the compounds discussed in wellness and research circles have never run a controlled human trial at all; their evidence base is a stack of rodent studies. When those studies were done before 2016, or outside the U.S. funding system entirely, there was no requirement to include female animals or to break the results down by sex.
The consequence is concrete. Take BPC-157: a peptide with genuine preclinical interest and heavy popular attention, but whose indexed literature is almost entirely male-animal work, with no controlled human trials and no sex-stratified outcomes. Or tirzepatide and semaglutide: here the human trials are large and did enroll many women, yet questions specific to female physiology, cycle-phase effects, interactions with oral contraceptive absorption, were rarely a pre-specified analysis. The women were in the room; the sex-specific questions often were not asked.
Throughout this database, an empty female-evidence field is labeled 'unstudied', a real finding, not a formatting gap. It means no qualifying study was located. It is never evidence that a compound is safe, and never evidence that it is harmful. It is the honest shape of the missing data.
Reading research with the gap in mind
None of this means peptide research is worthless, or that findings in male animals tell us nothing. It means the burden of proof runs the right direction. When a claim about a compound in women rests on a study that enrolled no women, that is a gap to name, not a detail to smooth over. When a dose figure circulating online traces back to male-rodent data, extrapolating it to a woman's body is an assumption wearing the costume of a fact.
This site exists to keep that distinction visible. For every compound we report how many indexed studies included women and whether any analyzed results by sex, and we show the blank spaces as blank. The history above is why those blanks are so common. The rest of the work is refusing to fill them with guesses.